** Drugmaker's U.S. shares drop as much as 7.4 pct to $15.89, Toronto shares as much as 7.5 pct to C$21.33
** Company's talks to sell its Salix unit to Takeda Pharmaceutical Co Ltd for about $10 bln have broken down, WSJ reports, citing sources (on.wsj.com/2gIIs9u)
** Though talks can be revived, Valeant is now focused on building Salix rather than selling it, report says
** Valeant said in early November it was in talks with third parties to sell its Salix stomach-drug business and other assets, but did not name the companies
** Valeant took charge of $1.05 bln in Q3, reflecting lower fair value of some U.S. businesses, mainly Salix, which makes treatments irritable bowel syndrome and diarrhea
** Up to Tuesday's close, company's U.S. and Canadian shares had dropped 83 percent this year as steep drug price increases and unorthodox use of a specialty pharmacy under previous leadership drew scrutiny from politicians and regulators.